Clinical trials · New York, NY
Neoplasms clinical trials in New York
We’re tracking 194 recruiting neoplasms studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT05859074RecruitingPhase 1
Testing MQ710 injections alone or with pembrolizumab for advanced cancers
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
New York, New YorkAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
New York, New YorkAges 18 years+ - NCT05253651RecruitingPhase 3
Tucatinib plus trastuzumab with chemo for HER2+ metastatic colon cancer
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
New York, New YorkAges 18 years+ - NCT06885034RecruitingPhase 1/Phase 2
Testing a New Drug for Advanced Colon, Rectal, or Pancreatic Cancer
This study tests an experimental drug, alone or combined with other treatments, for advanced colon, rectal, or pancreatic cancer that hasn't responded to standard options or cannot be removed by surgery. The goal is to see if it is safe and if it helps shrink or slow the cancer.
New York, New YorkAges 18 years+ - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
New York, New YorkAges 18 years+ - NCT05642611RecruitingPhase 3
Cooling and compression for nerve protection during chemotherapy
This study tests whether using cooling and/or compression on the arms or legs can prevent nerve damage that can happen from certain chemotherapy drugs. If you get eligible chemo soon, this may help lower the chance of painful numbness or tingling during treatment.
New York, New YorkAges 18 years+ - NCT06150157RecruitingPhase 1
Study of JNJ-88549968 for CALR-mutated blood cancers
This study tests an experimental drug called JNJ-88549968 in people with certain blood cancers (essential thrombocythemia or myelofibrosis) that have a CALR gene mutation. It may offer a new treatment option for those who haven't responded well to other therapies.
New York, New YorkAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
New York, New YorkAges Any age - NCT06941272RecruitingPhase 1/Phase 2
Study of patritumab deruxtecan for children with hard-to-treat solid tumors
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
New York, New YorkAges 1 month–17 years - NCT06276764Enrolling by invitation
A study tracking a new procedure for pancreatic cysts (IPMN)
This study follows patients with a type of pancreatic cyst called IPMN who receive the LINFU procedure, a treatment that uses sound waves and microbubbles. Researchers want to see how well it works and monitor safety.
New York, New YorkAges 18–90 - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
New York, New YorkAges 18 years+ - NCT07129252RecruitingPhase 1/Phase 2
A study of CRN09682 for NET and other solid tumors
This trial tests a new drug called CRN09682 for people with neuroendocrine tumors (NETs) or other solid tumors that have grown despite treatment and show a specific marker on scans. The goal is to see if the drug is safe and works against these cancers.
New York, New YorkAges 18 years+ - NCT06833073RecruitingPhase 2
Study of an mRNA vaccine and BCG for bladder cancer
This trial tests an experimental mRNA vaccine (V940) combined with BCG therapy for people with high-risk non-muscle invasive bladder cancer that hasn't spread. It aims to see if the vaccine can help the immune system better fight the cancer.
New York, New YorkAges 18 years+ - NCT06411821RecruitingPhase 2
Ulixertinib for people with histiocytic neoplasms
This trial tests an oral targeted therapy called ulixertinib for people with histiocytic neoplasms (a rare group of blood cell disorders). It aims to see if the drug can shrink tumors or control the disease in patients who have not responded to other treatments.
New York, New YorkAges 12 years+ - NCT06780176Recruiting
Breast cancer risk study for people in Florida
This study looks at breast cancer risk factors and outcomes by inviting people who are getting breast biopsies or are new breast patients at certain Florida hospitals to complete a survey. It aims to better understand what affects breast cancer risk and treatment results.
New York, New YorkAges 18 years+ - NCT06500455RecruitingPhase 3
Standard vs longer radiation for brain metastases
This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.
New York, New YorkAges 18 years+ - NCT06513962RecruitingPhase 3
Triptorelin to protect ovaries in young women with cancer
This study tests whether a medicine called triptorelin can protect the ovaries in young women and teens receiving strong chemotherapy for cancer. If you are newly diagnosed with a cancer (other than breast cancer) and are about to get certain chemotherapy drugs, this trial may help preserve your fertility.
New York, New YorkAges Up to 39 years - NCT05999994RecruitingPhase 2
Testing new drugs for children and young adults with cancer
This trial tests several experimental drugs for children and young adults with cancer. It aims to find safe and effective treatments by matching participants to one of several drug studies based on their cancer type and health.
New York, New YorkAges 1–39 - NCT07362225Recruiting
MPN Progress Registry: Tracking Symptoms and Progression
This observational registry tracks symptoms, treatments, and disease changes over time in people diagnosed with myeloproliferative neoplasms (MPNs). By joining, you help doctors learn more about the condition and possibly contribute to better future care.
New York, New YorkAges 18 years+ - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
New York, New YorkAges 18 years+ - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
New York, New YorkAges 18 years+ - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
New York, New YorkAges 18 years+ - NCT05863195RecruitingPhase 3
Pump chemotherapy plus standard chemo for liver-only colorectal spread
This study tests adding a chemotherapy “pump” directly into the liver along with standard chemotherapy, compared with standard chemotherapy alone. It’s for adults with colorectal cancer that has spread to the liver but cannot be surgically removed, and who are responding to first chemotherapy.
New York, New YorkAges 18 years+
Hear when a new Neoplasms trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Neoplasms trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting neoplasms studies listed above.
- Memorial Sloan Kettering Cancer Center · 15 studies
- Memorial Sloan Kettering Monmouth · 7 studies
- Memorial Sloan Kettering Bergen · 6 studies
- Memorial Sloan Kettering Commack · 6 studies
- Memorial Sloan Kettering Nassau · 6 studies
- Memorial Sloan Kettering Westchester · 6 studies
- Montefiore Medical Center · 6 studies
- Memorial Sloan Kettering Basking Ridge · 5 studies
What taking part in a neoplasms study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting neoplasms studies in New York.
Common questions
- Are there neoplasms clinical trials near New York?
- Yes. We're currently tracking 194 recruiting neoplasms studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a neoplasms study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a neoplasms trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New neoplasms studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.